Studieoverzicht

Study name: REDUCING TUMOR BURDEN IN PATIENTS WITH STAGE IV EGFR POSITIVE NON-SMALL CELL LUNG CANCER: SAFETY AND FEASIBILITY TRIAL (TITANS TRIAL)

Histology	NSCLC, only non-squamous
Tumor stage	Stage III - IV
Host / recruiting site 1	Antoni van Leeuwenhoek	Enrollment	Recruiting
Therapy line	First line (1L)
Design	Single-center, open-label, non-randomized phase I/II safety and feasibility trial.
Intervention	Tumor burden reduction combining standard targeted therapy (EGFR-TKI, osimertinib) with early local consolidative therapy (such as stereotactic radiotherapy/SABR or surgery) to remaining tumor sites.
Key outcome parameters	Feasibility and safety (measured by toxicity scores and successful completion of the local treatment). Progression-free survival (PFS), local tumor control, and overall survival
Key inclusion criteria	• Confirmed diagnosis of Stage IV non-squamous NSCLC. • Documented activating EGFR mutation (e.g., exon 19 deletion or L858R). • WHO/ECOG 0–1
Key exclusion criteria	• Prior systemic therapy for stage IV • Severe, uncontrolled comorbidities (e.g., severe interstitial lung disease, unstable cardiac conditions). • Pure squamous cell histology
Contact information	Log in voor de contactinformatie